Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Nobori And Uncoated Stent In Coronary Attack

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by NAUSICA Investigators
NPO International TRI Network
Information provided by (Responsible Party):
Shigeru Saito, NAUSICA Investigators Identifier:
First received: July 20, 2011
Last updated: October 16, 2014
Last verified: October 2014

Drug-eluting stents reduce rates of restenosis and reintervention, as compared with uncoated stents. Data are limited regarding the safety and efficacy of Nobori (Biolimus A9 Eluting Stent) in primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). Accordingly, the investigators will compare the outcomes of primary PCI for AMI between patients receiving Nobori versus uncoated stents.

Condition Intervention
Acute Myocardial Infarction
Device: Biolimus A9 eluting stents
Procedure: uncoated stent

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Clinical Trial of Nobori Versus Uncoated Stents In Acute Myocardial Infarction

Resource links provided by NLM:

Further study details as provided by NAUSICA Investigators:

Primary Outcome Measures:
  • major adverse cardiac and cerebrovascular events (MACE) [ Time Frame: 1 year ] [ Designated as safety issue: Yes ]
    MACE includes all-cause death, myocardial infarction, cerebrovascular events, and target lesion revascularization

Secondary Outcome Measures:
  • major adverse cardiac and cerebrovascular events (MACE) [ Time Frame: 1 week ] [ Designated as safety issue: Yes ]
    MACE includes all-cause death, myocardial infarction, cerebrovascular events, and target lesion revascularization

  • stent thrombosis [ Time Frame: 1 week and 1 year ] [ Designated as safety issue: Yes ]
  • target lesion revascularization [ Time Frame: 1 year ] [ Designated as safety issue: No ]

Estimated Enrollment: 1400
Study Start Date: July 2011
Estimated Study Completion Date: July 2017
Estimated Primary Completion Date: July 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Nobori
subjects receiving Biolimus A9 eluting stent implantation
Device: Biolimus A9 eluting stents
implantation of Biolimus A9 eluting stents
Other Name: Nobori® Drug Eluting Stent made by Terumo Corporation
Sham Comparator: Uncoated stents
subjects receiving uncoated stent implantation
Procedure: uncoated stent
implantation of any uncoated bare metal stents currently available in Japan


Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • age more than 20 years old
  • chest pain lasting more than 20 min
  • symptoms beginning within 12 hours before characterization
  • electrocardiogram showing ST-segment elevation or new appearance of left bundle branch block
  • increase in cardiac enzymes to more than 5-fold the normal laboratory values
  • infarct-related vessel are anatomically suitable for percutaneous revascularization
  • patients gave their signed, informed consent

Exclusion Criteria:

  • previous stent implantation within 30 days
  • allergy to any of the followings : aspirin, heparin, clopidogrel, biolimus A9 or its derivatives, stainless steel 316L, PLA (Poly-Lactic Acid) Polymer or its derivatives, and contrast media
  • elective surgery scheduled within 6 months
  • renal insufficiency with creatinine level of more than 2.5 mg/dL
  • patients associated with bleeding and/or clotting disorders, and those refusing blood transfusion
  • history of massive gastrointestinal or urinary tract bleeding within 6 months
  • patients currently enrolled in other clinical trials
  • pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01401036

Contact: Shigeru Saito, MD +81-467-46-1717 ext 10490
Contact: Saeko Takahashi, MD +81-467-46-1717

Shonan Atsugi Hospital Recruiting
Atsugi, Kanagawa, Japan, 243-0033
Contact: Shinji Tanaka, MD    81-46-223-3636      
Shonan Kamakura General Hospital Recruiting
Kamakura, Kanagawa, Japan, 247-8533
Contact: Saeko Takahashi, MD    +81-467-46-1717   
Tokyo nishi tokusyukai hospital Recruiting
Akishima, Japan
Contact: Hiroshi Domae         
Tokai University Hachioji Hospital Recruiting
Hachioji, Japan
Contact: Takashi Matsukage         
Hakodate Municipal Hospital Recruiting
Hakodate, Japan
Contact: Yasuhiro Makita, MD         
Principal Investigator: Yasuhiro Makita, MD         
Hiratsuka kyosai hospital Recruiting
Hiratsuka, Japan
Contact: Yuko Onishi, MD         
Tokai University Hospital Recruiting
Isehara, Japan
Contact: Yuji Ikari         
Ishikawa Prefectural Central Hospital Recruiting
Ishikawa, Japan
Contact: Kenji Miwa, MD         
Kanazawa Cardiovascular Hospital Recruiting
Kanazawa, Japan
Contact: Masanobu Nakamura, MD         
Kasukabe chuo general Hospital Recruiting
Kasukabe, Japan
Contact: Minoru Shimizu, MD         
Komaki Municipal Hospital Recruiting
Komaki, Japan
Contact: Katsuhiro Kawaguchi, MD         
Kyoto Katsura Hospital Recruiting
Kyoto, Japan
Contact: Shigeru Nakamura, MD         
Hayama Heart Center Recruiting
Miura, Japan
Contact: Hideki Ueno, MD         
Omuta Tenryo Hospital Recruiting
Omuta, Japan
Contact: Takuro Yamashita         
Osaki citizen hospital Recruiting
Osaki, Japan
Contact: Kaoru Iwabuchi         
Saga Medical University Hospital Recruiting
Saga, Japan
Contact: Yutaka Hikichi, MD         
Saga-ken Medical Center Koseikan Recruiting
Saga, Japan
Contact: Kenji Sadamatsu, MD         
Sapporo Hogashi Tokusyukai Hospital Recruiting
Sapporo, Japan
Contact: Seiji Yamazaki, MD         
Jichi Medical University Hospital Recruiting
Shimotsuke, Japan
Contact: Katsuki Takaaki, MD         
Tokushima medical university hospital Recruiting
Tokushima, Japan
Contact: Yoshio Taketani         
Tokyo medical University hospital Recruiting
Tokyo, Japan
Contact: Nobuhiro Tanaka         
Toho University Hospital Recruiting
Tokyo, Japan
Contact: Kenji Wagatsuma, MD         
Toyama Prefectural Central Hospital Recruiting
Toyama, Japan
Contact: Kazuo Usuda, MD         
Urazoe general hospital Recruiting
Urazoe, Japan
Contact: Yuki Uehara         
Kanagawa Cardiovascular and Respiratory Center Recruiting
Yokohama, Japan
Contact: Kazuki Fukui, MD         
Saiseikai Yokohama Tobu Hospital Recruiting
Yokohama, Japan
Contact: Toshiya Muramatsu         
Yokohama Medical University Hospital Recruiting
Yokohama, Japan
Contact: Kiyoshi Hibi, MD         
Sponsors and Collaborators
Shigeru Saito
NPO International TRI Network
Principal Investigator: Shigeru Saito, MD NPO International TRI Network
  More Information

No publications provided

Responsible Party: Shigeru Saito, Director, Cardiology, Shonan Kamakura General Hospital, NAUSICA Investigators Identifier: NCT01401036     History of Changes
Other Study ID Numbers: 20110629
Study First Received: July 20, 2011
Last Updated: October 16, 2014
Health Authority: Japan: Institutional Review Board

Keywords provided by NAUSICA Investigators:
acute myocardial infarction

Additional relevant MeSH terms:
Myocardial Infarction
Cardiovascular Diseases
Heart Diseases
Myocardial Ischemia
Pathologic Processes
Vascular Diseases processed this record on November 24, 2014